These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 10942772

  • 1. Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs.
    Biere AL, Wood SJ, Wypych J, Steavenson S, Jiang Y, Anafi D, Jacobsen FW, Jarosinski MA, Wu GM, Louis JC, Martin F, Narhi LO, Citron M.
    J Biol Chem; 2000 Nov 03; 275(44):34574-9. PubMed ID: 10942772
    [Abstract] [Full Text] [Related]

  • 2. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.
    Uversky VN, Li J, Souillac P, Millett IS, Doniach S, Jakes R, Goedert M, Fink AL.
    J Biol Chem; 2002 Apr 05; 277(14):11970-8. PubMed ID: 11812782
    [Abstract] [Full Text] [Related]

  • 3. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
    Park JY, Lansbury PT.
    Biochemistry; 2003 Apr 08; 42(13):3696-700. PubMed ID: 12667059
    [Abstract] [Full Text] [Related]

  • 4. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
    Conway KA, Harper JD, Lansbury PT.
    Biochemistry; 2000 Mar 14; 39(10):2552-63. PubMed ID: 10704204
    [Abstract] [Full Text] [Related]

  • 5. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
    Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M.
    J Biol Chem; 1999 Apr 02; 274(14):9843-6. PubMed ID: 10092675
    [Abstract] [Full Text] [Related]

  • 6. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.
    Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL.
    J Biol Chem; 1999 Jul 09; 274(28):19509-12. PubMed ID: 10391881
    [Abstract] [Full Text] [Related]

  • 7. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
    Li J, Uversky VN, Fink AL.
    Biochemistry; 2001 Sep 25; 40(38):11604-13. PubMed ID: 11560511
    [Abstract] [Full Text] [Related]

  • 8. Parkinson's disease and other alpha-synucleinopathies.
    Goedert M.
    Clin Chem Lab Med; 2001 Apr 25; 39(4):308-12. PubMed ID: 11388653
    [Abstract] [Full Text] [Related]

  • 9. Alpha-synuclein aggregation.
    Bodles AM, Irvine GB.
    Protein Pept Lett; 2004 Jun 25; 11(3):271-9. PubMed ID: 15182228
    [Abstract] [Full Text] [Related]

  • 10. Synucleins and their relationship to Parkinson's disease.
    von Bohlen Und Halbach O.
    Cell Tissue Res; 2004 Oct 25; 318(1):163-74. PubMed ID: 15503152
    [Abstract] [Full Text] [Related]

  • 11. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.
    Galvin JE, Uryu K, Lee VM, Trojanowski JQ.
    Proc Natl Acad Sci U S A; 1999 Nov 09; 96(23):13450-5. PubMed ID: 10557341
    [Abstract] [Full Text] [Related]

  • 12. alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro.
    Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, Allsop D.
    Free Radic Biol Med; 2001 May 15; 30(10):1163-70. PubMed ID: 11369507
    [Abstract] [Full Text] [Related]

  • 13. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS.
    Li J-, Henning Jensen P, Dahlström A.
    Neuroscience; 2002 May 15; 113(2):463-78. PubMed ID: 12127102
    [Abstract] [Full Text] [Related]

  • 14. The synucleins.
    George JM.
    Genome Biol; 2002 May 15; 3(1):REVIEWS3002. PubMed ID: 11806835
    [Abstract] [Full Text] [Related]

  • 15. Residual structure, backbone dynamics, and interactions within the synuclein family.
    Sung YH, Eliezer D.
    J Mol Biol; 2007 Sep 21; 372(3):689-707. PubMed ID: 17681534
    [Abstract] [Full Text] [Related]

  • 16. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.
    Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT.
    Biochemistry; 2001 Jul 03; 40(26):7812-9. PubMed ID: 11425308
    [Abstract] [Full Text] [Related]

  • 17. Comparative Analysis of the Conformation, Aggregation, Interaction, and Fibril Morphologies of Human α-, β-, and γ-Synuclein Proteins.
    Jain MK, Singh P, Roy S, Bhat R.
    Biochemistry; 2018 Jul 03; 57(26):3830-3848. PubMed ID: 29851342
    [Abstract] [Full Text] [Related]

  • 18. Structural transformation and aggregation of human alpha-synuclein in trifluoroethanol: non-amyloid component sequence is essential and beta-sheet formation is prerequisite to aggregation.
    Li HT, Du HN, Tang L, Hu J, Hu HY.
    Biopolymers; 2002 Aug 05; 64(4):221-6. PubMed ID: 12115139
    [Abstract] [Full Text] [Related]

  • 19. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T.
    Li J, Uversky VN, Fink AL.
    Neurotoxicology; 2002 Oct 05; 23(4-5):553-67. PubMed ID: 12428728
    [Abstract] [Full Text] [Related]

  • 20. Sequence Determinants for Amyloid Fibrillogenesis of Human alpha-Synuclein.
    Zibaee S, Jakes R, Fraser G, Serpell LC, Crowther RA, Goedert M.
    J Mol Biol; 2007 Nov 23; 374(2):454-64. PubMed ID: 17936783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.